



October 6, 2006, Boca Raton, FL:

Contact:

Larry J. Lapila
Vice President
Business Development
info@bpirx.com

Breckenridge Pharmaceutical, Inc. has learned of the U.S. Food and Drug Administration (“FDA”) Press Release, dated October 5, 2006, concerning a consent decree entered by the FDA against Syntho Pharmaceuticals, Inc. and Intermax Pharmaceuticals, Inc. (“Syntho”). Breckenridge is in the process of obtaining an official copy of the consent decree and will provide additional information once we have completed our review.

Late today, October 6, Breckenridge was notified by Syntho of a Syntho-initiated recall of certain lots of its products. Syntho has commenced the recall process for all applicable products which are still in inventory down to the retail level. Breckenridge will cooperate fully with Syntho and Syntho’s recall procedures. Breckenridge previously ceased the sale and distribution of all products manufactured by Syntho on April 6, 2006. Since that time, we have discontinued items or have been meeting customer demand by using new contract manufacturers.

Breckenridge remains committed to the manufacturing of all its products in full compliance with the Federal Food, Drug, and Cosmetic Act and current good manufacturing practices. All Breckenridge products remain generally recognized as safe and effective under FDA’s June 2006 guidance, “Marketed Unapproved Drugs – Compliance Policy Guide.”

About Breckenridge:

Breckenridge Pharmaceutical, Inc., a privately-held pharmaceutical marketing research and development company founded in 1983, is headquartered in Boca Raton, FL, with offices in Berlin, CT, and Fairfield, NJ. Breckenridge markets over 100 products in many therapeutic categories to over 100 customers in all classes of trade.